New vaccines for yellow fever and rabies enter first human tests

NCT ID NCT06998004

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two new vaccines—one for yellow fever and one for rabies—in 112 healthy adults aged 18 to 40. The main goal was to check safety and see how well the vaccines trigger an immune response. Participants received different doses or a placebo to help find the best balance of safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AVX70120 (yellow fever vaccine) and AVX70481 (rabies vaccine)
What this could lead to
If successful, these vaccines could provide new options to prevent yellow fever and rabies, potentially improving protection for travelers and people in affected regions.
What could go wrong
This is a very early Phase 1 trial with only 112 healthy adults. The vaccines may not trigger a strong enough immune response or could have unexpected side effects. Much more testing is needed before they could be widely used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre for the Evaluation of Vaccination (CEV)

    Antwerp, Belgium

  • University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)

    Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.